July 3, 2014
Copyright 2014 Questex Media Group LLC All Rights Reserved
Social media technologies provide users with quick and fast sharing capability and the potential to reach a huge swath of other users. The sites also afford the same capabilities to healthcare providers, vendors, pharmaceutical companies, payers and everyone else within the healthcare industry.
To that end, it's nice to see the U.S. Food and Drug Administration (FDA) finally catch up with how consumers and patients are sharing information online, especially since medical device manufacturers, pharma companies and other healthcare professionals are doing the exact same thing.
In drafting a new federal guidance document on social media use, FDA offers medical device manufacturers and pharmaceutical companies insight on how to share benefit and risk information on 23 electronics digital platforms, ranging from Twitter and blogs to online paid search programs. Specifically, it calls for a balance between risk and benefit information posted to online platforms.
The guidance arrived several months after the FDA announced its intention to track social media talk about product risks. "The objective of this requirement is to provide FDA with the resources needed to use social media to inform and evaluate FDA risk communications," a solicitation notice published to the Federal Business Opportunities website in March said.
Doctors, nurses, pharmacists and healthcare consultants from the U.S. make up most of the healthcare professionals who use Twitter, according to research by Creation Healthcare, a London-based research and training consultancy. U.S. healthcare professionals make up 31 percent of the 75,000 worldwide total of healthcare professionals who turn to the social media site to "tweet" information about healthcare policy, research, individual medicines and treatments for the disease.
Still, social media, in general--for med device and pharma companies, as well as health payers and providers--is about actively influencing consumers, educating and empowering them to drive measurable results, according to a Deloitte University Press article published earlier this year.
Health attorney and FierceHealthIT Editorial Advisory Board member David Harlow recently called the social media guidance "a great leap forward" in healthcare and I agree. As Thomas Abrams, director of the FDA's director of the Office of Prescription Drug Promotion noted in a blog post to the agency's website, it's important to keep drug advertisers--as well as medical device manufacturers--both honest and balanced.
Quality News Today is an ASQ member benefit offering quality related news
from around the world every business day.